ProCE Banner Events

ESR1 Mutations in Metastatic HR+ HER2- Breast Cancer: Testing and Treatment

This presentation offers a comprehensive review of ESR1 mutations in hormone receptor-positive (HR+) HER2-negative metastatic breast cancer, focusing on their role in breast cancer biology, patient outcomes, treatment decision-making, and clinical practice. The session will discuss the role of ESR1 mutations, current guidelines for ESR1 mutation testing and treatment, and the evolving treatment landscape. It will also highlight findings from major clinical trials involving patients with relapsed HR+ HER2-negative metastatic breast cancer, both with and without ESR1 mutations.

Learning Objectives

  • Understand the role of ESR1 mutations in HR+ HER2- metastatic breast cancer biology
  • Review current guidelines for ESR1 mutation testing and treatment, and their clinical importance
  • Summarize the current treatment landscape and recent data updates from key clinical trials in patients with relapsed HR+ HER2- metastatic breast cancer, with or without ESR1 mutations, and discuss their implications for clinical practice and patient outcomes
Time and location

Tuesday, January 21, 2025

6:15 PM - 6:45 PM Eastern Time (ET)

Virtual

Faculty
Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Sponsored By

Stemline

ProCE Banner